Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

Annals of Hematology

Volumn 89, Issue 11, 2010, Pages 1133-1140

  Buda, Gabriele ^a   Ricci, Deborah ^b   Huang, C Chris ^b   Favis, Reyna ^b   Cohen, Nadine ^b   Zhuang, Sen H ^b   Harousseau, Jean Luc ^c   Sonneveld, Pieter ^d   Bladé, Joan ^e   Orlowski, Robert Z ^f  

^a UNIVERSITY OF PISA   (Italy)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c HÔTEL DIEU   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f NONE

Author keywords

Bortezomib; MDR1; MRP1; Multiple myeloma; Pegylated liposomal doxorubicin; SNP

Indexed keywords

BORTEZOMIB; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MACROGOL DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; P-GLYCOPROTEIN 2; PYRAZINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC CORRELATION; GENETIC MODEL; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIPLE MYELOMA; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; KAPLAN-MEIER ESTIMATE;

EID: 77956962955     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0992-3     Document Type: Article

References (38)

1. SK Kumar TM Therneau MA Gertz, et al. 2004 Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 867 874 1:CAS:528: DC%2BD2cXmtlSgu70%3D 10.4065/79.7.867 15244382
2. JJ Shah RZ Orlowski 2009 Proteasome inhibitors in the treatment of multiple myeloma Leukemia 23 1964 1979 1:CAS:528:DC%2BD1MXhtl2hsrvN 10.1038/leu.2009.173 19741722
3. MA Dimopoulos E Kastritis SV Rajkumar 2008 Treatment of plasma cell dyscrasias with lenalidomide Leukemia 22 1343 1353 1:CAS:528: DC%2BD1cXosFSmsr0%3D 10.1038/leu.2008.123 18509355
4. JP Laubach A Mahindra CS Mitsiades, et al. 2009 The use of novel agents in the treatment of relapsed and refractory multiple myeloma Leukemia 23 2222 2232 1:CAS:528:DC%2BD1MXhsFKns7bK 10.1038/leu.2009.179 19741729
5. M Dimopoulos A Spencer M Attal, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123 2132 1:CAS:528:DC%2BD2sXhtlGis7nN 10.1056/NEJMoa070594 18032762 (Pubitemid 350146107)
6. DM Weber C Chen R Niesvizky, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133 2142 1:CAS:528:DC%2BD2sXhtlGis7bM 10.1056/NEJMoa070596 18032763 (Pubitemid 350146108)
7. RZ Orlowski PM Voorhees RA Garcia, et al. 2005 Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies Blood 105 3058 3065 1:CAS:528: DC%2BD2MXjtlSmtbo%3D 10.1182/blood-2004-07-2911 15626743
8. SE Biehn DT Moore PM Voorhees, et al. 2007 Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin Ann Hematol 86 211 216 1:CAS:528: DC%2BD2sXhtVamsbg%3D 10.1007/s00277-006-0220-3 17146676 (Pubitemid 46195994)
9. RZ Orlowski A Nagler P Sonneveld, et al. 2007 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 3892 3901 1:CAS:528:DC%2BD2sXhtFanu73M 10.1200/JCO.2006.10.5460 17679727 (Pubitemid 47477266)
10. Richardson P, Mitsiades C, Schlossman R et al. (2007) The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program 317-323.
11. DE Reece HA Leitch H Atkins, et al. 2008 Treatment of relapsed and refractory myeloma Leuk Lymphoma 49 1470 1485 10.1080/10428190802064941 18608859
12. SF Zhou 2008 Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition Xenobiotica 38 802 832 1:CAS:528:DC%2BD1cXpt1SnurY%3D 10.1080/00498250701867889 18668431
13. H Obata T Yahata J Quan, et al. 2006 Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer Anticancer Res 26 2227 2232 1:CAS:528:DC%2BD28XntV2msbY%3D 16821592
14. G Buda V Maggini S Galimberti, et al. 2007 MDR1 polymorphism influences the outcome of multiple myeloma patients Br J Haematol 137 454 456 1:CAS:528:DC%2BD2sXotVOgs70%3D 10.1111/j.1365-2141.2007.06605.x 17488488 (Pubitemid 46698294)
15. V Maggini G Buda A Martino, et al. 2008 MDR1 diplotypes as prognostic markers in multiple myeloma Pharmacogenet Genomics 18 383 389 1:CAS:528:DC%2BD1cXksFynu7w%3D 10.1097/FPC.0b013e3282f82297 18408561 (Pubitemid 351535939)
16. G Buda A Martino V Maggini, et al. 2009 MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma Acta Haematol 122 42 45 10.1159/000235820 19729888
17. H Minderman Y Zhou KL O'Loughlin MR Baer 2007 Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status Cancer Chemother Pharmacol 60 245 255 1:CAS:528:DC%2BD2sXltFSkt7w%3D 10.1007/s00280-006-0367-6 17096161 (Pubitemid 46742540)
18. H Rumpold C Salvador AM Wolf, et al. 2007 Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors Biochem Biophys Res Commun 361 549 554 1:CAS:528:DC%2BD2sXosF2jtLs%3D 10.1016/j.bbrc.2007.07.049 17662692 (Pubitemid 47187282)
19. ER Lepper K Nooter J Verweij, et al. 2005 Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2 Pharmacogenomics 6 115 138 1:CAS:528:DC%2BD2MXjt1ymsbY%3D 10.1517/14622416.6.2. 115 15882131 (Pubitemid 40613179)
20. JY Yin Q Huang Y Yang, et al. 2009 Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population Pharmacogenet Genomics 19 206 216 1:CAS:528:DC%2BD1MXjsVWqsbs%3D 10.1097/FPC.0b013e328323f680 19214144
21. T Nakamura K Tanaka T Matsunobu, et al. 2007 The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells Int J Oncol 31 803 811 1:CAS:528:DC%2BD2sXht1SjurbN 17786311
22. J Bladé D Samson D Reece, et al. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol 102 1115 1123 10.1046/j.1365-2141.1998.00930.x 9753033 (Pubitemid 28435189)
23. SK Kumar SV Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 1:CAS:528:DC%2BD1cXivFaktrk%3D 10.1182/blood-2007-10-116129 17975015
24. E Kastritis K Zervas A Symeonidis, et al. 2009 Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) Leukemia 23 1152 1157 1:CAS:528: DC%2BD1MXntFygtLw%3D 10.1038/leu.2008.402 19225533
25. Kumar S, Bladé J, Crowley J et al. (2009) Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Blood 114: Abstract 2878.
26. MS Raab K Podar I Breitkreutz, et al. 2009 Multiple myeloma Lancet 374 324 339 10.1016/S0140-6736(09)60221-X 19541364
27. Y Zhou B Barlogie JD Shaughnessy Jr 2009 The molecular characterization and clinical management of multiple myeloma in the post-genome era Leukemia 23 1941 1956 1:STN:280:DC%2BD1MjltFWqsQ%3D%3D 10.1038/leu.2009.160 19657360
28. M Tucci C Quatraro F Dammacco F Silvestris 2009 Role of active drug transporters in refractory multiple myeloma Curr Top Med Chem 9 218 224 1:CAS:528:DC%2BD1MXkvVSgtbg%3D 10.2174/156802609787521625 19200007
29. D Turk G Szakacs 2009 Relevance of multidrug resistance in the age of targeted therapy Curr Opin Drug Discov Devel 12 246 252 1:CAS:528: DC%2BD1MXnt12lu78%3D 19333870
30. IJ Letourneau RG Deeley SP Cole 2005 Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1) Pharmacogenet Genomics 15 647 657 1:CAS:528:DC%2BD2MXmsVyjt7w%3D 10.1097/01.fpc.0000173484.51807.48 16041243
31. K Takahashi T Shibata T Oba, et al. 2009 Multidrug-resistance-associated protein plays a protective role in menadione-induced oxidative stress in endothelial cells Life Sci 84 211 217 1:CAS:528:DC%2BD1MXhtVCrtb0%3D 10.1016/j.lfs.2008.11.021 19111752
32. D Keppler I Leier G Jedlitschky J Konig 1998 ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2 Chem Biol Interact 111-112 153 161 10.1016/S0009-2797(97)00158-0 9679551 (Pubitemid 28271941)
33. L Gianni EH Herman SE Lipshultz, et al. 2008 Anthracycline cardiotoxicity: from bench to bedside J Clin Oncol 26 3777 3784 10.1200/JCO.2007.14.9401 18669466
34. M Hitzl S Drescher H van der Kuip, et al. 2001 The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells Pharmacogenetics 11 293 298 1:CAS:528:DC%2BD3MXkvFeis74%3D 10.1097/00008571-200106000-00003 11434506 (Pubitemid 32537402)
35. T Mizutani M Masuda E Nakai, et al. 2008 Genuine functions of P-glycoprotein (ABCB1) Curr Drug Metab 9 167 174 1:CAS:528:DC%2BD1cXjsFyiur4%3D 10.2174/138920008783571756 18288958 (Pubitemid 351461005)
36. L Gil J Styczynski D Dytfeld, et al. 2007 Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia Anticancer Res 27 4021 4025 1:CAS:528:DC%2BD1cXlslarug%3D%3D 18225565
37. K Wiberg K Carlson A Aleskog, et al. 2009 In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies Med Oncol 26 193 201 1:CAS:528:DC%2BD1MXmtVKitrg%3D 10.1007/s12032-008-9107-6 19016012
38. J Adams M Kauffman 2004 Development of the proteasome inhibitor Velcade (Bortezomib) Cancer Invest 22 304 311 1:CAS:528:DC%2BD2cXjtl2qtb0%3D 10.1081/CNV-120030218 15199612 (Pubitemid 38725184)